Fund · Schwab U.S. Small-Cap ETF · measured from SEC filings
SCHA holdings
SCHA reports 1,707 holdings and behaves like 240.7 equally weighted ones, computed from its SEC Form N-PORT filing for 2026-05-31. The fact sheet publishes the first number; this page computes the second, and traces it across 27 quarters of filings.
Measured concentration
as of 2026-05-31Read this figure with the following in mind
1.6% of net assets is securities-lending cash collateral, excluded from the figure; counted as filed the fund would read 226.2
The figure below is what the filing says, published unchanged. What it may not do is sit beside a plain long-only fund and be read as the same quantity. How comparability is decided.
Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 100% at a quoted market price (level 1), 14 issuer countries.
What stands out
as of 2026-05-31SCHA's largest investment is Sandisk Corp/DE at 5.28% of net assets. Lumentum Holdings Inc and Revolution Medicines Inc follow; the three together are 7.22%. Ten companies are 10.53% of the fund; the other 1,697 share the rest. Among the 721 equity funds measured here, SCHA behaves like 240.7 holdings against a median of 42.4 — 5.7 times the median. Across 27 quarterly filings SCHA has become more concentrated: it behaved like 965.7 at 2019-11-30 and 240.7 at 2026-05-31. Between the 2026-02-28 and 2026-05-31 filings 30 positions were added and 45 dropped; 11.9% of the weight moved.
Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.
Every filing since 2019
27Between 2019-11-30 and 2026-05-31, SCHA went from behaving like 965.7 equally weighted positions to 240.7 — 75% fewer, while its top ten went from 2.45% to 10.53% of net assets. Read across the funds on the concentration-over-time table.
| Period | Holdings | Effective | Top 10 | Largest |
|---|---|---|---|---|
| 2026-05-31 | 1,707 | 240.7 | 10.53% | 5.28% |
| 2026-02-28 | 1,721 | 553.9 | 6.66% | 2.2% |
| 2025-11-30 | 1,739 | 806.1 | 4.12% | 0.77% |
| 2025-08-31 | 1,695 | 771.5 | 4.17% | 0.63% |
| 2025-05-31 | 1,713 | 795.1 | 3.64% | 0.57% |
| 2025-02-28 | 1,725 | 839.3 | 3.32% | 0.45% |
| 2024-11-30 | 1,738 | 887.5 | 2.91% | 0.41% |
| 2024-08-31 | 1,717 | 823.9 | 3.78% | 0.55% |
Earlier filings (19 more, back to 2019-11-30)
| Period | Holdings | Effective | Top 10 | Largest |
|---|---|---|---|---|
| 2024-05-31 | 1,718 | 833.3 | 3.64% | 0.64% |
| 2024-02-29 | 1,729 | 881.6 | 3.14% | 0.44% |
| 2023-11-30 | 1,737 | 917.7 | 2.55% | 0.33% |
| 2023-08-31 | 1,741 | 862.7 | 3.2% | 0.4% |
| 2023-05-31 | 1,752 | 901.7 | 2.84% | 0.36% |
| 2023-02-28 | 1,752 | 951.6 | 2.51% | 0.34% |
| 2022-11-30 | 1,746 | 961.4 | 2.54% | 0.3% |
| 2022-08-31 | 1,790 | 869.4 | 3.77% | 0.51% |
| 2022-05-31 | 1,806 | 895.8 | 3.52% | 0.44% |
| 2022-02-28 | 1,797 | 944.2 | 3.27% | 0.42% |
| 2021-11-30 | 1,740 | 976.1 | 2.9% | 0.35% |
| 2021-08-31 | 1,857 | 895.9 | 3.78% | 0.57% |
| 2021-05-31 | 1,836 | 943.3 | 3.49% | 0.55% |
| 2021-02-28 | 1,795 | 926.4 | 3.68% | 0.62% |
| 2020-11-30 | 1,746 | 922.6 | 3.37% | 0.43% |
| 2020-08-31 | 1,716 | 735.6 | 5.29% | 0.87% |
| 2020-05-31 | 1,714 | 801.6 | 4.21% | 0.75% |
| 2020-02-29 | 1,730 | 932.4 | 2.75% | 0.36% |
| 2019-11-30 | 1,732 | 965.7 | 2.45% | 0.27% |
One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.
As filed, collateral included
1.65% collateralSCHA's filing lists 1,708 positions including 1.65% of net assets in securities-lending cash collateral. Counted as filed the fund reads 226.2 effective holdings with a top ten of 11.79%; on its own investments — the figure above — it reads 240.7 with a top ten of 10.53%. The collateral is matched by a liability and is not a holding the fund chose; since 2026-09-18 every figure on this site sets it aside (methodology). Both numbers are in the data.
Largest positions, as filed
as of 2026-05-31The 15 largest of 1,707 positions in SCHA's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: listed with the point-in-time files, available on request.
| # | Position | Weight | Cumulative |
|---|---|---|---|
| 1 | Sandisk Corp/DE | 5.28% | 5.3% |
| 2 | Lumentum Holdings Inc | 1.29% | 6.6% |
| 3 | Revolution Medicines Inc | 0.65% | 7.2% |
| 4 | Sterling Infrastructure Inc | 0.56% | 7.8% |
| 5 | ATI Inc | 0.50% | 8.3% |
| 6 | MACOM Technology Solutions Holdings Inc | 0.50% | 8.8% |
| 7 | Nextpower Inc | 0.49% | 9.3% |
| 8 | MKS Inc | 0.46% | 9.7% |
| 9 | Coeur Mining Inc | 0.42% | 10.1% |
| 10 | TTM Technologies Inc | 0.38% | 10.5% |
| 11 | EchoStar Corp | 0.37% | 10.9% |
| 12 | Guardant Health Inc | 0.35% | 11.2% |
| 13 | SiTime Corp | 0.33% | 11.6% |
| 14 | Rambus Inc | 0.33% | 11.9% |
| 15 | Dycom Industries Inc | 0.32% | 12.2% |
By country of issuer
as of 2026-05-31Share of SCHA's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.
| Country | Share |
|---|---|
| United States | 96.43% |
| Bermuda° | 1.00% |
| United Kingdom | 0.52% |
| Ireland° | 0.42% |
| Puerto Rico° | 0.36% |
| Canada | 0.25% |
| Switzerland | 0.24% |
| Cayman Islands° | 0.24% |
Returns the fund reported
2019-09 – 2026-05Monthly total returns from Item B.5 of SCHA's own filings, 81 months on record. Not computed here and not from a price feed.
Cross-checked against a series computed separately from prices: median difference 0.06 percentage points over 81 months, which is roughly the distributions. Every month with the filing it came from: SCHA.json · all funds.
Who borrows SCHA's shares
2026-05-31The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2026-05-31, $364m was out to 13 borrowers, 1.60% of net assets. The largest, BARCLAYS CAPITAL INC., held 34.4% of it.
| Borrower | On loan | Share of the loan |
|---|---|---|
| BARCLAYS CAPITAL INC. | $125m | 34.4% |
| BNP PARIBAS SECURITIES CORP | $64m | 17.4% |
| MORGAN STANLEY & CO LLC | $53m | 14.6% |
| UBS SECURITIES LLC | $31m | 8.5% |
| BofA Securities, Inc. | $27m | 7.3% |
Cash collateral reported against the loan: 1.65% of net assets, 103.2% of the amount lent. That is a floor on the collateral, not the whole of it — collateral the fund does not hold as a position is not in this filing, so a figure under 100% is not evidence of under-collateralisation. How that figure behaves across all funds. Every quarter SCHA has filed, with each borrower: SCHA.json · all funds.
Since the previous filing
2026-02-28 → 2026-05-311,718 positions became 1,703: 30 added (0.7% of the fund at the later date), 45 dropped (1.7% at the earlier date). Half the sum of all weight changes, a turnover proxy: 11.9%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of SCHA compared this way, as a feed: changes.xml · all funds: filings received.
| Largest increases | 2026-02-28 | 2026-05-31 | Largest decreases | 2026-02-28 | 2026-05-31 |
|---|---|---|---|---|---|
| Sandisk Corp/DE | 2.20% | 5.28% | Hecla Mining Co | 0.39% | 0.25% |
| Sterling Infrastructure Inc | 0.31% | 0.56% | Rocket Cos Inc | 0.41% | 0.30% |
| Revolution Medicines Inc | 0.43% | 0.65% | Ensign Group Inc/The | 0.29% | 0.20% |
| DigitalOcean Holdings Inc | 0.09% | 0.26% | InterDigital Inc | 0.22% | 0.14% |
| Planet Labs PBC | 0.14% | 0.30% | Oshkosh Corp | 0.25% | 0.17% |
| Hut 8 Corp | 0.12% | 0.25% | Installed Building Products Inc | 0.17% | 0.10% |
New: Versant Media Group Inc (0.13%), Piper Sandler Cos (0.11%), Forgent Power Solutions Inc (0.10%), Madison Air Solutions Corp (0.08%), Twenty One Capital Inc (0.05%), VeraDermics Inc (0.04%). Gone: Confluent Inc (0.21%), Air Lease Corp (0.16%), Sealed Air Corp (0.14%), Arcellx Inc (0.12%), Piper Sandler Cos (0.12%), Amicus Therapeutics Inc (0.10%).
Asset categories and pricing
as of 2026-05-3198.29% equity, 1.70% short-term investment as filed; 100.0% carried at a quoted market price (fair-value level 1). Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.
Derivative exposure and counterparties
as of 2026-05-31A position count cannot describe a fund that uses derivatives, because a swap is filed at its unrealised gain, not its exposure. These are the notionals the fund itself reported, against net assets of $22.78B. Notional of an interest-rate or currency swap is not equity exposure.
Full detail for every fund that files derivatives: leverage.json (CC BY 4.0).
Neighbours by effective holdings, equity funds
10Every measured equity fund lined up by how many holdings it behaves like; these sit either side of SCHA (240.7). Same filings, same arithmetic. Position in this list says nothing about which fund is better.
| Fund | Reports | Behaves like | Top ten | As of |
|---|---|---|---|---|
| SPDW State Street(R) SPDR(R) Portfolio Developed World ex-US ETF | 2,444 | 227.8 | 14.04% | 2026-06-30 |
| JHMD John Hancock Multifactor Developed International ETF | 580 | 233.4 | 11.72% | 2026-06-30 |
| JMEE JPMorgan Small & Mid Cap Enhanced Equity ETF | 659 | 235.2 | 10.25% | 2026-06-30 |
| IXUS iShares Core MSCI Total International Stock ETF | 4,521 | 239.4 | 13.62% | 2026-07-31 |
| PSC Principal U.S. Small-Cap ETF | 507 | 239.5 | 11.25% | 2026-06-30 |
| BKIE BNY Mellon International Equity ETF | 978 | 243.1 | 12.21% | 2026-07-31 |
| USVM VictoryShares US Small Mid Cap Value Momentum ETF | 289 | 246.9 | 6.92% | 2026-06-30 |
| AVES Avantis Emerging Markets Value ETF | 1,883 | 252.9 | 12.26% | 2026-05-31 |
| VXUS Vanguard Total International Stock Index Fund | 8,832 | 253.6 | 13.32% | 2026-07-31 |
| IEFA iShares Core MSCI EAFE ETF | 2,630 | 267.8 | 11.97% | 2026-07-31 |
Essays that examine SCHA
0Mentions are detected across the full text of every article, so an appearance may be a passing comparison rather than the subject. Nothing here is a recommendation to buy or sell — see the disclaimer.